Helixgate

Helixgate

Uncategorized

AACR 2026: A Video Update from San Diego

Published

on

The American Association for Cancer Research (AACR) meeting is off and running in San Diego. Julianna LeMieux, PhD, Deputy Editor in Chief at GEN, and Damian Doherty, Editor in Chief at Inside Precision Medicine, are on the ground—in the talks, expo hall, and press room, covering as much of the news as they can. Here, they take a moment to chat about the first few days at the meeting.

The post AACR 2026: A Video Update from San Diego appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

A criminal sentence for OxyContin maker Purdue Pharma clears the way for completing its settlement

A judge is expected to sentence OxyContin maker Purdue Pharma to forfeit $225 million to the Justice Department on Tuesday, clearing the way for the company to finalize a settlement of thousands of lawsuits it faces over its role in the opioid crisis.

The penalty was agreed to in a 2020 pact to resolve federal civil and criminal probes it was facing. If the judge signs off, other penalties will not be collected in return for Purdue settling the other lawsuits.

Read the rest…

Read More

Published

on

A judge is expected to sentence OxyContin maker Purdue Pharma to forfeit $225 million to the Justice Department on Tuesday, clearing the way for the company to finalize a settlement of thousands of lawsuits it faces over its role in the opioid crisis.

The penalty was agreed to in a 2020 pact to resolve federal civil and criminal probes it was facing. If the judge signs off, other penalties will not be collected in return for Purdue settling the other lawsuits.

Read the rest…

Read More

Continue Reading

Uncategorized

Replimune cuts will leave over 200 jobless in Massachusetts

Published

on

Replimune is axing 144 employees at its Woburn headquarters and 80 at its Framingham manufacturing site. The cuts follow the FDA’s second rejection of the biotech’s advanced melanoma candidate.

Continue Reading

Uncategorized

Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs

Published

on

With programs from Eisai and Hansoh Pharmaceutical in hand, Tortugas Neuroscience has emerged with hopes of delivering daily oral treatments to patients with central nervous system conditions.

Continue Reading
Advertisement

Trending